摘要
目的探讨阿托伐他汀联合替格瑞洛治疗冠心病心绞痛患者的临床效果。方法选取76例冠心病心绞痛患者为研究对象并将其随机分为观察组和对照组,每组38例。对照组患者行阿托伐他汀治疗,观察组患者在对照组的基础上行替格瑞洛治疗,两组患者均持续治疗4周。比较两组患者的临床疗效、治疗前后的血清心肌酶指标和炎症因子水平,以及治疗期间的不良反应发生情况。结果观察组患者的治疗总有效率为94.74%,高于对照组患者治疗的78.95%(P<0.05)。治疗4周后,观察组患者的血清心肌肌钙蛋白I、肌酸激酶、肌酸激酶同工酶水平均低于对照组,血清白细胞介素-6、高敏C-反应蛋白、肿瘤坏死因子-α水平均低于对照组(均P<0.05)。两组患者治疗期间的不良反应发生率(5.26%比13.16%)差异无统计学意义(P>0.05)。结论阿托伐他汀联合替格瑞洛片治疗冠心病心绞痛患者的临床疗效显著,可有效地改善其心肌酶指标、炎症因子水平,安全性高。
Objective To investigate the clinical effect of atorvastatin combined with ticagrelor in the treatment of patients with angina pectoris of coronary heart disease.Methods A total of 76 patients with angina pectoris of coronary heart disease were selected as the research objects,and they were randomly divided into observation group and control group,with 38 cases in each group.The patients in the control group were treated with atorvastatin,while the patients in the observation group were treated with ticagrelor based on the control group,and both groups were treated for 4 weeks.The clinical efficacy,serum myocardial enzyme indices and inflammatory factors levels before and after treatment,and the occurrence of adverse reactions during treatment were compared between the two groups.Results The effective rate of the observation group was 94.74%,which was significantly higher than the 78.95%of the control group(P<0.05).After 4 weeks of treatment,the levels of serum cardiac troponin I,creatine kinase,creatine kinase isoenzymes,interleukin-6,high-sensitivity C-reactive protein,and tumor necrosis factor-αin the observation group were lower than those in the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(5.26%vs.13.16%)(P>0.05).Conclusion Atorvastatin combined with ticagrelor tablets has a significant clinical effect in the treatment of patients with angina pectoris of coronary heart disease,which can effectively improve their levels of myocardial enzyme indices and inflammatory factors,with high safety.
作者
李媛媛
LI Yuanyuan(Department of Cardiology,Public People's Hospital of Xinzheng,Zhengzhou 451100,Henan Province,China)
出处
《内科》
2022年第4期390-393,共4页
Internal Medicine
基金
河南省科技攻关计划项目(LHGJ20190734)。
关键词
阿托伐他汀
替格瑞洛
冠心病
心绞痛
心肌酶谱
炎症因子
Atorvastatin
Ticagrelor
Coronary heart disease
Angina pectoris
Myocardial enzymes spectrum
Inflammatory factor
